Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com/index.html

Latest From Daiichi Sankyo Co., Ltd.

Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm

Bookmark
  • News
By Joseph Haas, Lisa Takagi and Dexter Yan

Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

Deal Watch Business Strategies

10 Clinical Trials To Watch Out For In 2023

Bookmark
  • Analysis
By Alex Shimmings

Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.

Scrip Perspectives Clinical Trials

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

Bookmark
  • Analysis
By Ian Haydock

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.

Japan Business Strategies

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

Bookmark
  • Analysis
By Ian Haydock

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures. 

Japan Scrip Perspectives
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Ambit Biosciences Corporation
    • Asubio Pharmaceuticals, Inc.
    • Daiichi Sankyo RD Novare Co., Ltd.
    • Kitasato Daiichi Sankyo K.K.
    • Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
    • Plexxikon Inc.
    • Ranbaxy Laboratories Ltd.
    • Roxro Pharma, Inc.
    • Sankyo Pharma
    • Suntory Pharmaceutical
    • U3 Pharma AG
    • Daiichi Sankyo India Pharma Private Limited
    • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    • Zenotech Laboratories Ltd.
    • Daiichi Sankyo Vietnam Company Limited.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By